logo
Alibaba-backed Moonshot releases new Kimi AI model that beats ChatGPT, Claude in coding — and it costs less

Alibaba-backed Moonshot releases new Kimi AI model that beats ChatGPT, Claude in coding — and it costs less

CNBCa day ago
BEIJING — The latest Chinese generative artificial intelligence model to take on OpenAI's ChatGPT is offering coding capabilities — at a lower price.
Alibaba-backed startup Moonshot released on late Friday night its Kimi K2 model: a low-cost, open source large language model — the two factors that underpinned China-based DeepSeek's industry disruption in January. Open-source technology provides source code access for free, an approach that few U.S. tech giants have taken, other than Meta and Google to some extent.
Coincidentally, OpenAI CEO Sam Altman announced early Saturday that there would be an indefinite delay of its first open-source model yet again due to safety concerns. OpenAI did not immediately respond to a CNBC request for comment on Kimi K2.
One of Kimi K2's strengths is in writing computer code for applications, an area in which businesses see potential to reduce or replace staff with generative AI. OpenAI's U.S. rival Anthropic focused on coding with its Claude Opus 4 model released in late May.
In its release announcement on social media platforms X and GitHub, Moonshot claimed Kimi K2 surpassed Claude Opus 4 on two benchmarks, and had better overall performance than OpenAI's coding-focused GPT-4.1 model, based on several industry metrics.
"No doubt [Kimi K2 is] a globally competitive model, and it's open sourced," Wei Sun, principal analyst in artificial intelligence at Counterpoint, said in an email Monday.
"On top of that, it has lower token costs, making it attractive for large-scale or budget-sensitive deployments," she said.
The new K2 model is available via Kimi's app and browser interface for free unlike ChatGPT or Claude, which charge monthly subscriptions for their latest AI models.
Kimi is also only charging 15 cents for every 1 million input tokens, and $2.50 per 1 million output tokens, according to its website. Tokens are a way of measuring data for AI model processing.
In contrast, Claude Opus 4 charges 100 times more for input — $15 per million tokens — and 30 times more for output — $75 per million tokens. Meanwhile, for every one million tokens, GPT-4.1 charges $2 for input and $8 for output.
Moonshot AI said on GitHub that developers can use K2 however they wish, with the only requirement that they display "Kimi K2" on the user interface if the commercial product or service has more than 100 million monthly active users, or makes the equivalent of $20 million in monthly revenue.
Initial reviews of K2 on both English and Chinese social media have largely been positive, although there are some reports of hallucinations, a prevalent issue in generative AI, in which the models make up information.
Still, K2 is "the first model I feel comfortable using in production since Claude 3.5 Sonnet," Pietro Schirano, founder of startup MagicPath that offers AI tools for design, said in a post on X.
Moonshot has open sourced some of its prior AI models. The company's chatbot surged in popularity early last year as China's alternative to ChatGPT, which isn't officially available in the country. But similar chatbots from ByteDance and Tencent have since crowded the market, while tech giant Baidu has revamped its core search engine with AI tools.
Kimi's latest AI release comes as investors eye Chinese alternatives to U.S. tech in the global AI competition.
Still, despite the excitement about DeepSeek, the privately-held company has yet to announce a major upgrade to its R1 and V3 model. Meanwhile, Manus AI, a Chinese startup that emerged earlier this year as another DeepSeek-type upstart, has relocated its headquarters to Singapore.
Over in the U.S., OpenAI also has yet to reveal GPT-5.
Work on GPT-5 may be taking up engineering resources, preventing OpenAI from progressing on its open-source model, Counterpoint's Sun said, adding that it's challenging to release a powerful open-source model without undermining the competitive advantage of a proprietary model.
Kimi K2 is not the company's only recent release. Moonshot launched a Kimi research model last month and claimed it matched Google's Gemini Deep Research 's 26.9 score and beat OpenAI's version on a benchmark called "Humanity's Last Exam."
The Kimi research model even got a mention last week during Elon Musk's xAI release of Grok 4 — which scored 25.4 on its own on the "Humanity's Last Exam" benchmark, but attained a 44.4 score when allowed to use a variety of AI tools and web search.
"Kimi-Researcher represents a paradigm shift in agentic AI," said Winston Ma, adjunct professor at NYU School of Law. He was referring to AI's capability of simultaneously making several decisions on its own to complete a complex task.
"Instead of merely generating fluent responses, it demonstrates autonomous reasoning at an expert level — the kind of complex cognitive work previously missing from LLMs," Ma said. He is also author of "The Digital War: How China's Tech Power Shapes the Future of AI, Blockchain and Cyberspace."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Russian rouble, stock market gain after Trump's statement on Russia
Russian rouble, stock market gain after Trump's statement on Russia

Yahoo

time34 minutes ago

  • Yahoo

Russian rouble, stock market gain after Trump's statement on Russia

MOSCOW (Reuters) -The Russian rouble reversed losses against the dollar and rose against China's yuan after U.S. President Donald Trump warned he would impose "very severe tariffs" on Russia if no deal on a peaceful settlement is made in 50 days. As of 1605 GMT, the rouble was 0.2% weaker at 78.10 per U.S. dollar after hitting 78.75 during the day, according to LSEG data based on over-the-counter quotes. The rouble is up about 45% against the dollar since the start of the year. Trump announced new weapons for Ukraine on Monday and threatened to hit buyers of Russian exports with sanctions, expressing frustration with Russian President Vladimir Putin due to the lack of progress in ending the war in Ukraine. "Trump performed below market expectations," said analyst Artyom Nikolayev from Invest Era. "He gave 50 days during which the Russian leadership can come up with something and extend the negotiation track. Moreover, Trump likes to postpone and extend such deadlines." Against the Chinese yuan, the most traded foreign currency in Russia, the rouble strengthened 0.8% to 10.87 after weakening by over 1% on Friday. The Russian stock market rose 2.7% after Trump's statement, according to the Moscow Stock Exchange.

Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Yahoo

time40 minutes ago

  • Yahoo

Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech. The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. Following the completion of the nearly billion-dollar deal, LaNova Medicines will become an indirect wholly owned subsidiary of Sino. A timeline of 30 business days has been set by the companies to finalise the deal. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. LaNova's drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. Sino stated the acquisition would strengthen its research and development capabilities, subsequently enhancing competitiveness and innovation in the oncology market. LaNova's pipeline has already been raided twice by US big pharma companies. In 2023, AstraZeneca licensed LM-305, a G-protein targeting-ADC, for $600m. A year later, MSD outlaid more than $3bn to secure global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. According to Sino, LaNova Medicines has two projects in the registration clinical stage, six projects in the Phase I/II clinical trial stage, and more than ten projects in the preclinical research stage. In a statement, Sino said: 'Through the in-depth synergy and integration of the advantageous resources of both parties, not only will the potential value of LaNova Medicines be fully released, but also [Sino's] innovation capability will be comprehensively enhanced." The company added that the transaction will help towards its 'strategic goal of advancing towards a world-class innovative pharmaceutical enterprise'. China's economy grew 5.2% year-on-year in Q2, defying the lingering effects of US President Trump's trade war and reinforcing its position as the world's top exporter. This economic resilience is mirrored in China's growing role in the global oncology market. Despite economic pressures, licensing promising drug candidates from Chinese biotechs is becoming a well-trodden path for many US big pharma companies. Licensing deals between US and Chinese biopharma companies hit record highs last year, a 280% increase from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Sino Biopharma spends $951m to acquire China-based LaNova Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Dollar Rallies on Higher T-note Yields
Dollar Rallies on Higher T-note Yields

Yahoo

time40 minutes ago

  • Yahoo

Dollar Rallies on Higher T-note Yields

The dollar index (DXY00) today is up +0.47%. The dollar is seeing support as the 10-year T-note rose +3.6 bp and the 30-year T-bond yield rose back above 5% for the first time in 1.5 months. The rise in Treasury yields supported the dollar's interest rate differentials. Today's US CPI report generated some favorable initial media coverage as the June core CPI report of +0.2% m/m was slightly below expectations of +0.3%. However, there were some scattered signs of upside pressure from tariffs, and that pressure is expected to increase in the coming months. Also, both the headline and core CPI reports on a year-over-year basis rose from May. Latest US Tariff Threats Boost the Dollar Dollar Supported by Latest US Tariff Threats Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Specifically, the June US CPI rose +0.3% m/m, which was in line with market expectations, while the year-over-year figure of +2.7% was slightly worse than expectations of +2.6% and was up from May's +2.4%. The June US core CPI rose +0.2% m/m, which was slightly better than expectations of +0.3%. On a year-over-year basis, the June US core CPI was in line with expectations at +2.9% y/y but rose from May's +2.8%. Today's CPI report did not improve market expectations for Fed easing, which were little changed after the CPI report. Federal funds futures prices are discounting the chances for a -25 bp rate cut at 3% at the July 29-30 FOMC meeting and at 65% at the following meeting on Sep 16-17. There was some positive trade news today after Treasury Secretary Bessent said that US-China trade talks are in a "very good place," which reduced safe-haven demand for the dollar. He also said the US-China deadline is flexible and told market participants "not to worry about August 12." Mr. Bessent confirmed that the Trump administration has told Nvidia that a license for the sale of its advanced H20 GPU chips to Chinese firms will be granted and is "all part of a mosaic" in the US-China negotiations. He also said he hopes to meet with Chinese Vice Premier He Lifeng in August. EUR/USD (^EURUSD) is down -0.36% on strength in the dollar. The euro was also undercut by today's -2.4 bp decline in the 10-year bund yield, which reduced the euro's interest rate differentials. The euro saw underlying support from news that the July German ZEW expectations index rose +5.2 points to 52.7 from 47.5 in June, which was stronger than expectations for an increase to 50.4. The euro also saw underlying support as the May Eurozone industrial production report of +1.7% m/m and +3.7% y/y was stronger than market expectations of +1.0% m/m and +2.2% y/y. Swaps are pricing in a 2% chance of a -25 bp rate cut by the ECB at the July 24 policy meeting. USD/JPY (^USDJPY) is up +0.76% on dollar strength. Additionally, the yen remains under pressure due to concerns about the upcoming upper house election in Japan on July 20. The promises by Japan's ruling Liberal Democratic Party of cash handouts to voters and promises of lower taxes by the opposition have sparked concerns of fiscal deterioration, which are bearish for the yen. August gold (GCQ25) is down -2.2 (-0.07%), and September silver (SIU25) is down -0.402 (-1.04%). Precious metals are trading lower on today's +0.47% rise in the dollar index and the +3.6 bp rise in the 10-year T-note yield. Sep silver is seeing some long liquidation after falling back from Monday's contract high. July 2025 silver today fell back from Monday's 14-year high on the nearest-futures chart. Precious metals prices also fell back today on some favorable trade news as Treasury Secretary Bessent claimed that US-Chinese trade talks were in a "very good place." On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store